tuoyi toripalimab injection 80mg 2ml per vial

Description

Indication & Scope

Toripalimab Injection (TuoYi®) is a recombinant humanized anti-PD-1 monoclonal antibody. It binds to PD-1 on T cells, blocks PD-1/PD-L1 immune checkpoint pathway, restores T cell anti-tumor immune function, activates systemic anti-tumor immunity to eliminate tumor cells.

Mechanism

Block PD-1 checkpoint pathway, restore T cell anti-tumor immune activity
Drug class

PD-1 Immune Checkpoint Inhibitor / Monoclonal Antibody Anti-tumor Immunotherapy
Clinical use

Multiple malignant tumors including melanoma, urothelial carcinoma, nasopharyngeal carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer and hepatocellular carcinoma

Specification

Generic Name	Toripalimab Injection
Brand Name	TuoYi®
Ingredient	Toripalimab
Dosage Form	Injection
Package	80mg(2ml)/vial
Conditions Treated	Advanced melanoma, urothelial carcinoma, pretreated nasopharyngeal carcinoma; first-line combination therapy for nasopharyngeal carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, triple-negative breast cancer and hepatocellular carcinoma.
Taboos	Hypersensitivity to toripalimab or any excipients
Place of origin	Shanghai,China
Priscription Type	Prescription Drug, Class B Medicare
Storage Conditions	Store at 2℃-8℃, protected from light, do not freeze
Manufacturer	Shanghai Junshi Bioscience Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	S20191003
Date of Revision	January 22, 2026
Shelf Life	24 months

How to use ?

Recommended Dose: 3mg/kg intravenous infusion once every 2 weeks, or 240mg fixed dose intravenous infusion once every 3 weeks; given over 30–60 minutes, do not rapid bolus

Time: Intravenous slow infusion over 30–60 minutes, do not give as rapid IV push

Interaction: Risk of severe immune-related adverse events when combined with immunosuppressants/corticosteroids; monitor closely; do not mix directly with other infusions

Side effects: Immune-related adverse reactions (thyroid dysfunction, immune pneumonitis, hepatitis, colitis, nephritis), fever, fatigue, rash, anemia, infusion reactions, elevated liver enzymes, myelosuppression

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support